ClinicalTrials.gg
CompletedNCT07840339G-PTERYGOIDUpdated Sep 29, 2026

Guided Pterygoid Implants: an Accuracy Study

An interventional study of 3D Printed Digital Surgical Guide in Edentulous Maxilla, Atrophic, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Aug 2024, registered Sep 2026).
Updated Sep 29, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
20 Years to 60 Years
Sex
All
01

Study summary

The aim of this clinical study is to evaluate the accuracy of placing pterygoid implants using custom-made surgical guides in patients with atrophied posterior maxilla. The study focuses on measuring how closely the actual implant position matches the virtual preoperative plan in terms of angle and distance.

Read the detailed description

Rehabilitation of the atrophic posterior maxilla remains a surgical challenge. This study utilizes pterygoid implants as a graftless solution. For each participant, a digital workflow is followed: a cone-beam computed tomography (CBCT) scan and an intraoral scan are performed to design a custom-made surgical guide. Following implant placement, a postoperative CBCT is obtained. The accuracy is then evaluated by superimposing the planned and actual implant positions to calculate the coronal, apical, and angular deviations.

02

Conditions studied

  • Edentulous Maxilla, Atrophic

Browse trials for

Keywords

  • Bone support vs mucosa support
  • Pterygoid implant
  • Accuracy of the surgical guide
  • Computer-Aided Design
03

In context

Atrophic Maxilla

30 studies on the registry are indexed under Atrophic Maxilla; 11 are open to participants now.

This study's enrollment of 9 is below the median of 16 across 27 interventional studies indexed under Atrophic Maxilla.

Browse Atrophic Maxilla studies →

Lead sponsor

Tanta University is the lead sponsor of 1,010 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 29, 2026. See what changed

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The age of the patients is between 20 and 60 years.
  • Partially and completely maxillary edentulous patients whose sinus pneumatization and refuse other treatment options.
  • Bone height related to the sinus is less than 5 mm.

Exclusion criteria

Exclusion Criteria:

  • Soft and hard tissue pathology at the operation site
  • Patients with uncontrolled systemic disease
  • Prior radiation therapy
  • Previous chemotherapy and/or antiresorptive agents
  • Heavy smoking (e.g., two packs per day)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Guided Pterygoid Implant

    Patients with atrophic posterior maxilla receiving pterygoid implants using a custom-made digital surgical guide to evaluate placement accuracy.

    Device: 3D Printed Digital Surgical Guide

Interventions

  • Device3D Printed Digital Surgical Guide

    A custom-made surgical template designed using technology based on the patient's CBCT and intraoral scans. It is used to guide the surgical drills and the placement of pterygoid implants according to a pre-planned virtual position to ensure accuracy

06

What researchers measure

Primary outcomes

  1. Accuracy of custom-made surgical guide

    Evaluation of the deviation between the virtual preoperative plan and the actual postoperative implant position. This includes angular (measured in angle degrees) and linear deviation (measured in mm).

    Time frame: Immediately postoperative

07

Study locations

1 site
  • (Faculty of Dentistry - Tanta University
    Tanta, Gharbia Governorate 35111, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Aug 2025, 11 months.

Of 20 interventional studies with no phase under Atrophic Maxilla, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 32. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 25, 2026
StartActual
Aug 22, 2024
Primary completionActual
Aug 8, 2025
CompletionActual
Apr 10, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 2 removed; 2 exclusion criteria edited, 2 added
What changed in the criteria
Inclusion criteria
  • Removed-
  • RemovedThe patients recruited for the study were selected according to the following criteria:
  • EditedThe age of the patients is between 20- and 60 years.
Exclusion criteria
  • EditedSoft and hard tissue pathology at the operation site • Systemically:
  • AddedPatients with uncontrolled systemic disease
  • AddedPrevious chemotherapy and/or antiresorptive agents
  • Edited1. Patients with uncontrolled systemic disease 2. Previous chemotherapy and/or antiresorptive agents 3. Heavy smoking (e.g., two packs per day)
Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedAccuracy of custam custom-made surgical guideTime frame: Immediately postoperative
Sep 29, 2026
Registered
First appeared on the registry
Sep 25, 2026
Show all 2 updates
  1. Sep 29, 2026
    Eligibility 1 inclusion criterion edited, 2 removed; 2 exclusion criteria edited, 2 added
    What changed in the criteria
    Inclusion criteria
    • Removed-
    • RemovedThe patients recruited for the study were selected according to the following criteria:
    • EditedThe age of the patients is between 20- and 60 years.
    Exclusion criteria
    • EditedSoft and hard tissue pathology at the operation site • Systemically:
    • AddedPatients with uncontrolled systemic disease
    • AddedPrevious chemotherapy and/or antiresorptive agents
    • Edited1. Patients with uncontrolled systemic disease 2. Previous chemotherapy and/or antiresorptive agents 3. Heavy smoking (e.g., two packs per day)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedAccuracy of custam custom-made surgical guideTime frame: Immediately postoperative
    + 3 other changes: index terms, responsible party and conditions
  2. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07840339
Lead sponsor
Tanta University
Responsible party
Ahmed Gamal Taha Abushahba (Principal Investigator, Tanta University) — Principal investigator
First posted
Sep 25, 2026
Start date
Aug 22, 2024
Primary completion
Aug 8, 2025
Completion
Apr 10, 2026
Last update
Sep 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion